Please Wait
Applying Filters...
menu
    • menu
    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    UNII-UF6PC17XAV

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1650550-25-6, Ag-221 mesylate, Enasidenib mesilate, Enasidenib methanesulfonate, Enasidenib (mesylate), Uf6pc17xav
    Molecular Formula
    C20H21F6N7O4S
    Molecular Weight
    569.5  g/mol
    InChI Key
    ORZHZQZYWXEDDL-UHFFFAOYSA-N
    FDA UNII
    UF6PC17XAV
    Enasidenib Mesylate is the mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
    2.1.2 InChI
    InChI=1S/C19H17F6N7O.CH4O3S/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25;1-5(2,3)4/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32);1H3,(H,2,3,4)
    2.1.3 InChI Key
    ORZHZQZYWXEDDL-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    UF6PC17XAV
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 1650550-25-6

    2. Ag-221 Mesylate

    3. Enasidenib Mesilate

    4. Enasidenib Methanesulfonate

    5. Enasidenib (mesylate)

    6. Uf6pc17xav

    7. Enasidenib Mesylate [usan]

    8. Cc-90007

    9. 1650550-25-6 (mesylate)

    10. Enasidenib Mesylate (usan)

    11. 2-propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)

    12. 2-methyl-1-[4-(6-trifluoromethyl-pyridin-2-yl)-6-(2-trifluoromethyl-pyridin-4-ylamino)-[1,3,5]triazin-2-ylamino]-propan-2-ol Mesylate

    13. Methanesulfonic Acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol

    14. Unii-uf6pc17xav

    15. Idhifa (tn)

    16. Chembl3989931

    17. Enasidenib Mesylate [mi]

    18. Schembl16448052

    19. Dtxsid501027943

    20. Bcp26166

    21. Ex-a1972

    22. Enasidenib Mesylate [who-dd]

    23. Hy-18690a

    24. S4929

    25. Enasidenib Mesylate; Ag-221 Mesylate

    26. At36098

    27. Cs-7541

    28. Enasidenib Mesylate [orange Book]

    29. Ac-31319

    30. D11044

    31. Q27291054

    32. 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)- 6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin- 2-yl)amino)propan-2-ol Methanesulfonate

    2.4 Create Date
    2015-02-23
    3 Chemical and Physical Properties
    Molecular Weight 569.5 g/mol
    Molecular Formula C20H21F6N7O4S
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count17
    Rotatable Bond Count6
    Exact Mass569.12799232 g/mol
    Monoisotopic Mass569.12799232 g/mol
    Topological Polar Surface Area172 Ų
    Heavy Atom Count38
    Formal Charge0
    Complexity727
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Pharmacology and Biochemistry
    4.1 FDA Pharmacological Classification
    4.1.1 Pharmacological Classes
    Isocitrate Dehydrogenase 2 Inhibitors [MoA]; Isocitrate Dehydrogenase 2 Inhibitor [EPC]